Drug Trial Radar · NCT02839707
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
444
Actual
Start
Jun 23, 2017
Primary completion
May 9, 2023
Study completion May 11, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NRG Oncology
- First posted
- Jul 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
Conditions
- Fallopian Tube High Grade Serous Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Fallopian Tube Clear Cell Adenocarcinoma
- Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Fallopian Tube Undifferentiated Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian Undifferentiated Carcinoma
- Recurrent Platinum-Resistant Fallopian Tube Carcinoma
- Recurrent Platinum-Resistant Ovarian Carcinoma
- Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
- Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
- Recurrent Primary Peritoneal Undifferentiated Carcinoma
Interventions
AtezolizumabDrug
Given IV
BevacizumabBiological
Given IV
Computed TomographyProcedure
Undergo CT
Pegylated Liposomal Doxorubicin HydrochlorideDrug
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLT) of Experimental RegimensTime frame: Up to 28 days
- Progression Free Survival (PFS) (Phase II)Time frame: From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years
- PFS (Phase III)Time frame: From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years.
- Overall Survival (OS) (Phase III)Time frame: From study enrollment to the date of death regardless of the cause, assessed up to 5 years
Locations
919 sites in 2 countries. Site status is shown where the registry gives one.
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
CTCA at Western Regional Medical Center
Goodyear, Arizona
Kingman Regional Medical Center
Kingman, Arizona
Cancer Center at Saint Joseph's
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Mercy San Juan Medical Center
Carmichael, California
Eden Hospital Medical Center
Castro Valley, California
Community Cancer Institute
Clovis, California
University Oncology Associates
Clovis, California
John Muir Medical Center-Concord
Concord, California
Sutter Davis Hospital
Davis, California
Epic Care-Dublin
Dublin, California
Kaiser Permanente Dublin
Dublin, California
Mercy Cancer Center - Elk Grove
Elk Grove, California
Bay Area Breast Surgeons Inc
Emeryville, California
Epic Care Partners in Cancer Care
Emeryville, California
Kaiser Permanente-Fontana
Fontana, California
Showing 40 of 919 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.